FDA accepts Emergent BioSolutions’ anthrax vaccine candidate for review

By PBR Staff Writer

The US Food and Drug Administration (FDA) has agreed to review Emergent BioSolutions’ Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted).